Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

New England Journal of Medicine - Tập 381 Số 25 - Trang 2416-2428 - 2019
Isabelle Ray‐Coquard1, Patricia Pautier1, Sandro Pignata1, David Pérol1, Antonio González‐Martín1, Regina Berger1, Keiichi Fujiwara1, Ignace Vergote1, Nicoletta Colombo1, Johanna Mäenpää1, Frédèric Selle1, Jalid Sehouli1, Domenica Lorusso1, Eva Maria Guerra Alía1, Alexander Reinthaller1, Shoji Nagao1, Claudia Lefeuvre‐Plesse1, Ulrich Canzler1, Giovanni Scambia1, Alain Lortholary1, Frederik Marmé1, Pierre Combe1, Nikolaus de Gregorio1, Manuel Rodrigues1, Paul Buderath1, Coraline Dubot1, Alexander Burges1, Benoît You1, Éric Pujade-Lauraine1, Philipp Harter1
1From Centre Léon Bérard (I.R.-C., D.P.), University Claude Bernard Lyon 1 (I.R.-C.), and Centre Hospitalier Lyon-Sud (B.Y.), Lyon, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) (I.R.-C., P.P., F.S., C.L.-P., A.L., P.C., M.R., C.D., B.Y., E.P.-L.), Groupe Hospitalier Diaconesses Croix Saint-Simon (F.S.), Hôpital Européen Georges Pompidou (P.C.), Institut Curie, Hôpital Claudius Régaud (M.R.), and Association de Recherche Cancers Gynécologiques (ARCAGY) (E.P.-L.), Paris, Gustave Roussy, Villejuif (P.P.), Centre Eugène Marquis, Rennes (C.L.-P.), Centre Catherine de Sienne Hôpital Privé du Confluent, Nantes (A.L.), and Institut Curie, Hôpital René Huguenin, Saint Cloud (C.D.) - all in France; the Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, and Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Naples (S.P.), University of Milan-Bicocca and European Institute of Oncology IRCCS, and Mario Negri Gynecologic Oncology Group (MANGO) (N.C.), and Fondazione IRCCS Istituto Nazionale Tumori and MITO (D.L.), Milan, and Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica, and MITO, Rome (G.S.) - all in Italy; M.D. Anderson Cancer Center Madrid (A.G.-M.), Grupo Español de Investigación en Cáncer de Ovario (GEICO) (A.G.-M., E.M.G.A.), and Hospital Universitario Ramón y Cajal (E.M.G.A.) - all in Madrid; Medical University of Innsbruck, University Clinic for Gynecology and Obstetrics (R.B.), and Arbeitsgemeinschaft Gynäkologische Onkologie Study Group (AGO)-Austria (R.B., A.R.), Innsbruck, and Medical University of Vienna, Vienna (A.R.) - all in Austria; Saitama Medical University International Medical Center, Hidaka (K.F.), Gynecologic Oncology Trial and Investigation Consortium (GOTIC), Moroyama-cho (K.F., S.N.), and Hyogo Cancer Center, Akashi (S.N.) - all in Japan; University Hospital Leuven, Leuven Cancer Institute, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG) - both in Leuven, Belgium (I.V.); Tampere University and University Hospital, Tampere, Finland (J.M.); the Nordic Society of Gynecologic Oncology (NSGO), Copenhagen (J.M.); and Charité-Medical University of Berlin (Campus Virchow Klinikum), Berlin (J.S.), German Society of Gynecologic Oncology (AGO) (J.S., U.C., F.M., N.G., P.B., A.B., P.H.), Universitätsklinikum Essen (P.B.), and Kliniken Essen Mitte (P.H.), Essen, Universitätsklinikum Carl Gustav Carus, Technische

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1056/NEJMoa1103799

10.1056/NEJMoa1104390

10.1093/annonc/mdt333

10.1093/annonc/mdz062

10.1093/annonc/mdx011

10.1200/JCO.19.01009

10.1016/S1470-2045(15)00086-8

10.1056/NEJMoa1810858

10.1016/j.molcel.2015.10.040

10.1038/nature10166

10.1016/S1470-2045(14)70228-1

10.1056/NEJMoa1611310

10.1016/S0140-6736(17)32440-6

10.1200/JCO.2019.37.15_suppl.5505

10.1016/S1470-2045(14)70391-2

10.1093/annonc/mdz018

10.1016/j.ejca.2012.02.059

10.1111/IGC.0b013e3181d3caa8

10.1097/IGC.0000000000000478

10.1016/j.ygyno.2013.11.008

10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E

10.1158/1078-0432.CCR-17-1327

10.1158/0008-5472.CAN-10-2352

10.1016/S1470-2045(17)30469-2

10.1016/S1470-2045(16)30376-X